Immunotherapeutic Approaches for the Treatment of Glioblastoma Multiforme: Mechanism and Clinical Applications

Suprava Das; Banendu Sunder Dash; Thejas P. Premji; Jyh Ping Chen

doi:10.3390/ijms241310546

Immunotherapeutic Approaches for the Treatment of Glioblastoma Multiforme: Mechanism and Clinical Applications

Suprava Das, Banendu Sunder Dash, Thejas P. Premji, Jyh Ping Chen^*

^*Corresponding author for this work

Department of Chemical and Materials Engineering

Chang Gung University

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Glioma is one of the most aggressive types of primary brain tumor with a high-grade glioma known as glioblastoma multiforme (GBM). Patients diagnosed with GBM usually have an overall survival rate of less than 18 months after conventional therapy. This bleak prognosis underlines the need to consider new therapeutic interventions for GBM treatment to overcome current treatment limitations. By highlighting different immunotherapeutic approaches currently in preclinical and clinical trials, including immune checkpoint inhibitors, chimeric antigen receptors T cells, natural killer cells, vaccines, and combination therapy, this review aims to discuss the mechanisms, benefits, and limitations of immunotherapy in treating GBM patients.

Original language	English
Article number	10546
Journal	International Journal of Molecular Sciences
Volume	24
Issue number	13
DOIs	https://doi.org/10.3390/ijms241310546
State	Published - 23 06 2023

Bibliographical note

Publisher Copyright:
© 2023 by the authors.

Keywords

brain cancer
clinical application
glioblastoma multiforme
immunotherapy
Glioma/therapy
Humans
Immunotherapy
Combined Modality Therapy
Glioblastoma/pathology
Killer Cells, Natural/pathology
Brain Neoplasms/pathology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/ijms241310546

Cite this

@article{21db37e3812d48aabd900f53c951944a,

title = "Immunotherapeutic Approaches for the Treatment of Glioblastoma Multiforme: Mechanism and Clinical Applications",

abstract = "Glioma is one of the most aggressive types of primary brain tumor with a high-grade glioma known as glioblastoma multiforme (GBM). Patients diagnosed with GBM usually have an overall survival rate of less than 18 months after conventional therapy. This bleak prognosis underlines the need to consider new therapeutic interventions for GBM treatment to overcome current treatment limitations. By highlighting different immunotherapeutic approaches currently in preclinical and clinical trials, including immune checkpoint inhibitors, chimeric antigen receptors T cells, natural killer cells, vaccines, and combination therapy, this review aims to discuss the mechanisms, benefits, and limitations of immunotherapy in treating GBM patients.",

keywords = "brain cancer, clinical application, glioblastoma multiforme, immunotherapy, Glioma/therapy, Humans, Immunotherapy, Combined Modality Therapy, Glioblastoma/pathology, Killer Cells, Natural/pathology, Brain Neoplasms/pathology",

author = "Suprava Das and Dash, \{Banendu Sunder\} and Premji, \{Thejas P.\} and Chen, \{Jyh Ping\}",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = jun,

day = "23",

doi = "10.3390/ijms241310546",

language = "英语",

volume = "24",

journal = "International Journal of Molecular Sciences",

issn = "1661-6596",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "13",

}

TY - JOUR

T1 - Immunotherapeutic Approaches for the Treatment of Glioblastoma Multiforme

T2 - Mechanism and Clinical Applications

AU - Das, Suprava

AU - Dash, Banendu Sunder

AU - Premji, Thejas P.

AU - Chen, Jyh Ping

PY - 2023/6/23

Y1 - 2023/6/23

N2 - Glioma is one of the most aggressive types of primary brain tumor with a high-grade glioma known as glioblastoma multiforme (GBM). Patients diagnosed with GBM usually have an overall survival rate of less than 18 months after conventional therapy. This bleak prognosis underlines the need to consider new therapeutic interventions for GBM treatment to overcome current treatment limitations. By highlighting different immunotherapeutic approaches currently in preclinical and clinical trials, including immune checkpoint inhibitors, chimeric antigen receptors T cells, natural killer cells, vaccines, and combination therapy, this review aims to discuss the mechanisms, benefits, and limitations of immunotherapy in treating GBM patients.

AB - Glioma is one of the most aggressive types of primary brain tumor with a high-grade glioma known as glioblastoma multiforme (GBM). Patients diagnosed with GBM usually have an overall survival rate of less than 18 months after conventional therapy. This bleak prognosis underlines the need to consider new therapeutic interventions for GBM treatment to overcome current treatment limitations. By highlighting different immunotherapeutic approaches currently in preclinical and clinical trials, including immune checkpoint inhibitors, chimeric antigen receptors T cells, natural killer cells, vaccines, and combination therapy, this review aims to discuss the mechanisms, benefits, and limitations of immunotherapy in treating GBM patients.

KW - brain cancer

KW - clinical application

KW - glioblastoma multiforme

KW - immunotherapy

KW - Glioma/therapy

KW - Humans

KW - Immunotherapy

KW - Combined Modality Therapy

KW - Glioblastoma/pathology

KW - Killer Cells, Natural/pathology

KW - Brain Neoplasms/pathology

UR - https://www.scopus.com/pages/publications/85164947510

U2 - 10.3390/ijms241310546

DO - 10.3390/ijms241310546

M3 - 文献综述

C2 - 37445721

AN - SCOPUS:85164947510

SN - 1661-6596

VL - 24

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

IS - 13

M1 - 10546

ER -

Immunotherapeutic Approaches for the Treatment of Glioblastoma Multiforme: Mechanism and Clinical Applications

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this